Bibliography
- Jansen TL. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers? Arthritis Res Ther 2010;12(1):103
- Lok ASF, McMahon BJ. AASLD Practice guideline update. Chronic hepatitis B: update 2009. Hepatology 2009;50:227; 661–662
- Charpin C, Guis S, Colson P, Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11(6):R179
- Caporali R, Bobbio-Pallavicini F, Atzeni F, Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers with rheumatic diseases. Arthritis Care Res 2010;62:749-54
- Loras C, Saro C, Gonzalez-Huix F, Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57-63
- Tamori A, Koike T, Goto H, Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011;46:556-64
- Vassipoulos D, Apostolopoulou A, Hadziyannis E, Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5
- Gianizzi C, Sebastiani GD, Manganelli S, Galeazzi M. Safety of anti-TNF agents in rheumatic potential carriers of occult hepatitis B virus. J Rheumatol 2011;38:780-1
- Lan JL, Chen YM, Hsieh TY, Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011;70:1719-25
- Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012;12:179-92
- Vassilopoulos D. Sould we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Int Med 2011;22:572-5
- Saleem B, Keen H, Goeb V, Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636-42